Eisai Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expected net sales of JPY 730,000 million, operating profit of JPY 78,000 million, profit for the year of JPY 61,000 million and earnings per share attributable to owners of the parent of JPY 211.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,478 JPY | +1.65% | -2.28% | -8.14% |
07-02 | Eli Lilly Alzheimer's drug approved by US FDA | RE |
07-02 | Eisai Repurchases 4.8 Billion Yen Worth of Shares in June | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.14% | 11.3B | |
+56.76% | 809B | |
+39.52% | 624B | |
-7.11% | 351B | |
+7.37% | 289B | |
+13.74% | 240B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.90% | 166B | |
-2.55% | 157B |
- Stock Market
- Equities
- 4523 Stock
- News Eisai Co., Ltd.
- Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022